Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery disease, announced today that its TVC Imaging System™ for the true vessel characterization of coronary artery disease will be highlighted in 13 presentations during the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT 2013). TCT 2013, the world's largest educational meeting specializing in interventional cardiovascular medicine, will be held October 27-November 1, 2013 at The Moscone Center in San Francisco.
The TVC Imaging System is a first-in-class intravascular imaging system that enables clinicians to assess both the structure and composition of obstructive plaque in the coronary arteries and to guide interventional treatments for better procedural outcomes. It integrates near-infrared spectroscopy (NIRS) lipid core plaque (LCP) detection technology and enhanced intravascular ultrasound (IVUS) imaging to visualize the presence of plaques, quantify the degree of vessel stenosis (narrowing) and identify lipid core plaques prone to rupturing and causing dangerous blood clots.
“We’re pleased to announce that our TVC Imaging System will be the focus of several presentations led by the world’s premier thought-leaders in interventional cardiology at this year’s TCT meeting,” said Don Southard, president and chief executive officer of Infraredx. “As the pioneer in true vessel characterization, Infraredx provides clinicians with a comprehensive solution to enhance diagnostic accuracy, improve procedural outcomes and potentially define treatment strategies.”
The schedule for presentations featuring the TVC Imaging System is as follows:
Monday, Oct. 28th
4:23 pm
Moscone West, 2nd Floor, Room 2007
How and When to Use IVUS, OCT, and NIRS for Procedural Guidance
Gary Mintz, M.D.
4:40 pm
Unraveling the ACS Culprit: Insights from NIRS-IVUS
David Erlinge, M.D., Ph.D
Moscone West, 2nd Floor, Room 2007
Tuesday, Oct. 29th
7:00 am
Moscone North, Rm 125
Integrating Physiology and Imaging into the Cath Lab: What Technology Should I use and How
and When Should I Use it?
William Fearon, M.D., Spencer Kubo, M.D., Emmanouil S. Brilakis, M.D., Ph.D., John
McB.Hodgson, M.D., Bon-Kwon Koo, M.D., Ph.D., Soo-Jin Kang, M.D.
11:45 am
Moscone South, Esplanade Level, Esplanade Ballroom
Plenary Session V. Live Cases II: New York-Presbyterian Hospital/Columbia University Medical
Center, New York, NY (Giora Weisz, M.D.)
Wednesday, Oct. 30th
2:00 pm - 6:10 pm
Vulnerable Plaque Detection and Treatment
Moscone South, Lower Level, Room 104
3:52 pm
Vulnerable Plaque Diagnosis by NIRS-IVUS (with case vigniettes): current Data and Prospect II
David Erlinge, M.D., Ph.D.
Moscone South, Lower Level, Room 104
Thursday, Oct. 31st
8:00 am-12: 00 pm
Next Generation Intravascular Imaging and Physiology: RF-IVUS, OCT, NIRS, iFR, CT-FFR
Moscone South, Lower Level, Room 104
9:05 am
Moscone South, Lower Level, Room 104
Can Detection of Stable Coronary Plaque Composition by OCT, RF-IVUS, or NIRSpectroscopy
Replace or Supplement Physiologic Lesion Assessment?
Akiko Maehara, M.D.
9:15 am
Moscone South, Lower Level, Room 104
Identifying and Managing Embolic-Prone Lesions: RF-IVUS, OCT, and NIRS
Emmanouil S. Brilakis, M.D., Ph.D.
9:25 am
Moscone South, Lower Level, Room 104
RF-IVUS, OCT, and NIRS Findings in Patients Presenting With STEMI
David Erlinge, M.D., Ph.D.
9:55 am
Moscone South, Lower Level, Room 104
Neoatherosclerosis: OCT and NIRS Findings and Their Clinical Implications
Ziad A. Ali, M.D., DPhil
10:30 am
Moscone South, Lower Level, Room 104
Geographic Miss: VH-IVUS, OCT, and NIRSFindings and Their Clinical Importance
Marco A. Costa, M.D., Ph.D.
11:30 am
Moscone South, Lower Level, Room 104
Case #5: NIRS Case
Giora Weisz, M.D.